In this video, Motley Fool health care analyst Brenton Flynn takes a look at Celgene (NASDAQ:CELG) and its cancer drug Abraxane. The company's shares received a boost on Monday after releasing phase 3 data showing that the drug had a statistically significant impact on survival rates for advanced pancreatic cancer. Flynn takes us through the likelihood of Abraxane getting approval from the Food and Drug Administration,  the growth potential in the market for this drug if it is approved, and what that could mean for this company's future.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.